BrainStorm Cell Therapeutics Inc. (BCLI): רווח למניה בשנים עשר החודשים האחרונים

Can Brainstorm Cell (BCLI) management adapt its R&D strategy following regulatory disputes? The answer lies in the development of the NurOwn platform and Phase 3 clinical trials for ALS aimed at accelerated FDA approval. However, geopolitics and sanctions are hindering biomaterial logistics, as evidenced by the company's revenue per employee, where the value remains at -2.01.

Investing in Brainstorm Cell (BCLI) requires a rigorous analysis of the actual yield per share. This metric reflects the net profit distributed across the total issuance for the year, excluding the impact of market noise. By analyzing the earnings per share history over 12 months, an investor assesses the monetization efficiency of the NurOwn platform. For a biotech company fighting ALS, this indicator confirms the transition from costly development to capital stability. The upward trend here serves as the primary criterion for asset quality.